Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone, which is in Phase 3 confirmatory trial for the treatment of negative symptoms in patients with schizophrenia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.

• Download SqueezeTrigger (TM) Report
• Download FrictionFactor Report
• Download Daily Short Volume Report
• Download Real-Time Short Volume Tool
• Download Failures to Deliver

• [05/06/2026 07:45 PDT] NERV Expected to Trade Up After Bullish Patterns Develop
• [05/04/2026 06:54 PDT] NERV Expected to Trade Up After Bullish Patterns Develop
• [04/27/2026 07:25 PDT] NERV Expected to Trade Up After Bullish Patterns Develop
• [04/09/2026 07:00 PDT] NERV Expected to Trade Down After Bearish Patterns Develop
• [04/08/2026 07:15 PDT] NERV Expected to Trade Down After Bearish Patterns Develop
• [04/08/2026 06:46 PDT] NERV Expected to Trade Down Short Term
• [04/01/2026 07:22 PDT] NERV Expected to Trade Up After Bullish Patterns Develop
• [03/23/2026 08:16 PDT] NERV SqueezeTrigger Price is $0.00. There is $0 That Short Sellers Still Need To Cover.
• [03/12/2026 13:20 PDT] NERV SqueezeTrigger Price is $0.00. There is $0 That Short Sellers Still Need To Cover.